WO2003006657A3 - Elements de regulation du gene destines a la therapie genique pour la prevention et le diagnostic de metastases ainsi que le traitement des tumeurs par therapie genique - Google Patents

Elements de regulation du gene destines a la therapie genique pour la prevention et le diagnostic de metastases ainsi que le traitement des tumeurs par therapie genique Download PDF

Info

Publication number
WO2003006657A3
WO2003006657A3 PCT/EP2002/007857 EP0207857W WO03006657A3 WO 2003006657 A3 WO2003006657 A3 WO 2003006657A3 EP 0207857 W EP0207857 W EP 0207857W WO 03006657 A3 WO03006657 A3 WO 03006657A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene
gene therapy
metastases
tumours
diagnosis
Prior art date
Application number
PCT/EP2002/007857
Other languages
German (de)
English (en)
Other versions
WO2003006657A2 (fr
Inventor
Karsten Brand
Original Assignee
Custos Biotechnologie Gmbh
Karsten Brand
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10159128A external-priority patent/DE10159128A1/de
Application filed by Custos Biotechnologie Gmbh, Karsten Brand filed Critical Custos Biotechnologie Gmbh
Priority to AU2002328897A priority Critical patent/AU2002328897A1/en
Publication of WO2003006657A2 publication Critical patent/WO2003006657A2/fr
Publication of WO2003006657A3 publication Critical patent/WO2003006657A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé de production de promoteurs/amplificateurs qui peuvent être induits par des tissus tumoraux et/ou des métastases. Les promoteurs/amplificateurs sont adaptés à une utilisation dans des systèmes vectorettes de thérapie génique, notamment aux fins de traitement de cancers et métastases.
PCT/EP2002/007857 2001-07-13 2002-07-15 Elements de regulation du gene destines a la therapie genique pour la prevention et le diagnostic de metastases ainsi que le traitement des tumeurs par therapie genique WO2003006657A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002328897A AU2002328897A1 (en) 2001-07-13 2002-07-15 Gene-regulatory elements for gene therapy, for the prevention and diagnosis of metastases and for the gene therapy of tumours

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10133560.1 2001-07-13
DE10133560 2001-07-13
DE10159128A DE10159128A1 (de) 2001-07-13 2001-12-01 Genregulatorische Elemente zur Gentherapie, zur Prävention und Diagnose von Metastasen bzw. zur Gentherapie von Tumoren
DE10159128.4 2001-12-01

Publications (2)

Publication Number Publication Date
WO2003006657A2 WO2003006657A2 (fr) 2003-01-23
WO2003006657A3 true WO2003006657A3 (fr) 2003-11-13

Family

ID=26009675

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/007857 WO2003006657A2 (fr) 2001-07-13 2002-07-15 Elements de regulation du gene destines a la therapie genique pour la prevention et le diagnostic de metastases ainsi que le traitement des tumeurs par therapie genique

Country Status (2)

Country Link
AU (1) AU2002328897A1 (fr)
WO (1) WO2003006657A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000028092A1 (fr) * 1998-11-05 2000-05-18 Ortho-Mcneil Pharmaceutical, Inc. Methode permettant de generer des profils d'expression genique
WO2000061806A2 (fr) * 1999-04-09 2000-10-19 Arcturus Engineering, Inc. Reseau generique d'adnc ou de proteines destine a des bioanalyses personnalisees
WO2000066176A2 (fr) * 1999-04-30 2000-11-09 Karsten Brand Agent pour la therapie genique et la prevention de metastases ainsi que pour la therapie genique de tumeurs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000028092A1 (fr) * 1998-11-05 2000-05-18 Ortho-Mcneil Pharmaceutical, Inc. Methode permettant de generer des profils d'expression genique
WO2000061806A2 (fr) * 1999-04-09 2000-10-19 Arcturus Engineering, Inc. Reseau generique d'adnc ou de proteines destine a des bioanalyses personnalisees
WO2000066176A2 (fr) * 1999-04-30 2000-11-09 Karsten Brand Agent pour la therapie genique et la prevention de metastases ainsi que pour la therapie genique de tumeurs

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRAND, K. ET AL.: "Treatment of Colorectal Liver Metastases by Adenoviral Transfer of Tissue Inhibitor of Metalloproteinases-2 into the Liver Tissue", CANCER RESEARCH, vol. 60, no. 20, 15 October 2000 (2000-10-15), pages 5723 - 5730, XP002235668 *
HAROON, Z.A. ET AL.: "Tissue Transglutaminase Is Expressed as a Host Response to Tumor Invasion and Inhibits Tumor Growth", LABORATORY INVESTIGATION, vol. 79, no. 12, December 1999 (1999-12-01), pages 1679 - 1686, XP008017379 *
HAYASHI, S. ET AL.: "Two promoters in expression of estrogen receptor messenger RNA in human breast cancer", CARCINOGENESIS, vol. 18, no. 3, March 1997 (1997-03-01), pages 459 - 464, XP002235667 *
WIDSCHWENDTER, M. ET AL.: "Loss of retinoic acid receptor beta expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer", EUROPEAN JOURNAL OF CANCER, vol. 34, February 1998 (1998-02-01), pages S17, XP004284726 *

Also Published As

Publication number Publication date
AU2002328897A1 (en) 2003-01-29
WO2003006657A2 (fr) 2003-01-23

Similar Documents

Publication Publication Date Title
WO2003002595A3 (fr) Nouveaux inhibiteurs de dipeptidylpeptidase iv et leurs utilisations en tant qu'agents anti-cancereux
WO2006138511A3 (fr) Composes et procedes pour le traitement du cancer
WO2003000928A3 (fr) Innovation en matiere de therapie anti-cancereuse
RS105304A (en) Methods of treating angiogenesis,tumor growth,and metastasis
WO2003083041A8 (fr) Anticorps specifiques au cripto
WO2004028454A3 (fr) 1, 3, 5-triazines destinees au traitement de maladies virales
WO2003013535A3 (fr) Moyens et methodes de traitement ameliore du cancer fondes sur mdr1
WO2004080425A3 (fr) Composes polypeptidiques permettant d'inhiber l'angiogenese et la croissance tumorale
WO2004110245A3 (fr) Polytherapie destinee au traitement du cancer
WO2004073615A3 (fr) Composes de deazaflavine et leurs methodes d'utilisation
WO2004104039A8 (fr) Antigenes tumoraux destines a la prevention et/ou au traitement du cancer
WO2005123908A3 (fr) Nouvelles lignees cellulaires cancereuses et leurs utilisations
WO2008052054A3 (fr) Synergie entre des cellules immunes activées et des thérapies contre le cancer classiques
WO2005123141A3 (fr) Polytherapie anticancereuse avec declencheur de l'expression de produit genique et d'agent de ciblage de produit genique
WO2004092212A3 (fr) Antigene tumoral bfa-5 pour la prevention et/ou le traitement du cancer
MXPA03007036A (es) Metodo de terapia para cancer.
WO2005085188A3 (fr) Composes et procedes pour la therapie antitumorale
AP2004003070A0 (en) The method of treating cancer.
WO2000061753A3 (fr) Compositions et methodes de depistage et de traitement du cancer du sein
WO2003006657A3 (fr) Elements de regulation du gene destines a la therapie genique pour la prevention et le diagnostic de metastases ainsi que le traitement des tumeurs par therapie genique
SG148035A1 (en) Gene products differentially expressed in cancerous breast cells and their methods of use
WO2003080800A3 (fr) Prevention et traitement de maladies au moyen d'angiogenese et/ou d'antigenes tumoraux
WO2005016958A3 (fr) Composes utilises pour traiter des tumeurs
AU2003212990A8 (en) Novel compositions and methods for the identification, assessment, prevention and therapy of ovarian cancer
AU2002366712A1 (en) Genetic markers and methods for the diagnosis, treatment and prevention of tumor metastasis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: FESTSTELLUNG EINES RECHTSVERLUSTS NACH REGEL 69(1) EPUE. EPUE FORM 1205A VOM 24.05.04

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP